Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC®

MALVERN, Pa. , July 15, 2024 /PRNewswire/ —

Endo, Inc. (OTCQX: NDOI) announced today the launch of tiopronin delayed-release tablets, a generic version of Travere Therapeutics’ THIOLA EC ^® .

“We’re proud to provide high-quality, affordable choices to healthcare providers and their appropriate patients,” said Scott Sims , Senior Vice President and General Manager, Endo Injectable Solutions & Generics. “The launch of tiopronin delayed-release tablets strengthens our generic product portfolio and underscores our reputation as a reliable supplier.”

The medication is used in combination with high fluid intake, alkali (low acid), and dietary changes to help prevent the formation of one type (cystine) of kidney stones in certain adult and pediatric patients.

As a demonstration of its commitment to patients, Endo is offering copay assistance for those who meet eligibility requirements. To learn more about Endo’s Patient Assistance Program, patients can call (833) 727-4357.

THIOLA EC ^® is a registered trademark of Mission Pharmacal Company.